Ilona Pylvaenaeinen

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

V. Koneti Rao, Sharon Webster, Virgil A. S. H. Dalm et al. · Blood · 2017 · 286 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial

Thomas Dörner, Martin Kaul, Antónia Szántó et al. · Annals of the Rheumatic Diseases · 2023 · 54 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab

Fabrice André, Mario Campone, SA Hurvitz et al. · Journal of Clinical Oncology · 2008 · 52 citations

Medicine, Oncology, Pharmacology +17

Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model

Johan Vansteenkiste, Benjamin Solomon, Michael Boyer et al. · Journal of Thoracic Oncology · 2011 · 35 citations · Full text

Medicine, Oncology, Pharmacology +12

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer

Benjamin Besse, Rebecca S. Heist, V.A. Papadmitrakopoulou et al. · Annals of Oncology · 2013 · 29 citations

Medicine, Oncology, Pharmacology +14